Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Arvinas, Inc. and its officers or directors [1] Company Developments - On May 1, 2025, Arvinas announced the removal of plans for a Phase 3 first-line combination trial with atirmociclib and a Phase 3 second-line combination trial with a CDK4/6 inhibitor from its joint development plan with Pfizer [3] - The decision to remove these trials was based on a review of emerging information, external data results, the evolving treatment landscape in metastatic breast cancer, and long-term capital allocation [3] - Arvinas also announced a workforce reduction of approximately one-third to streamline operations and enable efficient progression of its portfolio, with completion planned for the second quarter of 2025 [3] - Following this news, Arvinas's stock price fell by $2.39 per share, or 24.84%, closing at $7.23 per share on May 1, 2025 [3]

Core Viewpoint - Cable One, Inc. is under investigation for potential securities fraud and unlawful business practices following disappointing financial results and a significant stock price drop [1][3]. Financial Performance - On May 1, 2025, Cable One reported Q1 2025 earnings that fell significantly short of analyst expectations and announced the suspension of its dividend [3]. - Analysts from Keybanc described the results as "extremely disappointing," while Raymond James criticized management's optimism regarding future growth in broadband revenue and subscribers despite poor performance [3]. - Following the earnings report, Cable One's stock price plummeted by $109.48, or 41.79%, closing at $152.51 per share on May 2, 2025 [3]. Legal Investigation - Pomerantz LLP is investigating claims on behalf of Cable One investors regarding possible securities fraud or other unlawful business practices by the company and its officers/directors [1].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Capricor Therapeutics, Inc. and its officers or directors [1] Group 1: Company Developments - On May 5, 2025, Capricor announced that the FDA confirmed its intent to hold an advisory committee meeting regarding the Biologics License Application for deramiocel, a treatment for Duchenne muscular dystrophy cardiomyopathy [3] - Following this announcement, Capricor's stock price dropped by $3.00 per share, representing a decline of 29.13%, closing at $7.30 per share on May 6, 2025 [4] Group 2: Legal Investigation - Pomerantz LLP is reaching out to investors of Capricor to discuss claims related to potential securities fraud [1] - The firm has a long history in corporate, securities, and antitrust class litigation, having recovered significant damages for victims of securities fraud and corporate misconduct [5]

Core Viewpoint - Metallus Inc. is under investigation for potential securities fraud and unlawful business practices following disappointing financial results for Q1 2025, which led to a significant drop in stock price [1][3]. Financial Performance - Metallus reported non-GAAP earnings per share of $0.07 for Q1 2025, missing consensus estimates by $0.05 [3]. - The company's stock price fell by $1.48, or 11.31%, closing at $11.61 per share on May 9, 2025, following the earnings announcement [3]. Company Challenges - The CEO of Metallus indicated that the company experienced volatility in the defense supply chain during Q1 2025, attributed to customer manufacturing start-up challenges [3].

Core Viewpoint - EchoStar Corporation is under investigation for potential securities fraud and unlawful business practices, which has led to significant stock price declines following negative news regarding its compliance with federal requirements and financial obligations [1][3][4]. Group 1: Investigation and Legal Actions - Pomerantz LLP is investigating claims on behalf of EchoStar investors regarding possible securities fraud or unlawful business practices by the company and its officers [1]. - The investigation follows a Wall Street Journal article highlighting the Federal Communications Commission's (FCC) scrutiny of EchoStar's compliance with federal requirements for its Boost Mobile subsidiary [3]. Group 2: Stock Price Impact - Following the FCC's announcement, EchoStar's stock price dropped by $4.01, or 16.58%, closing at $20.18 on May 12, 2025 [3]. - On May 30, 2025, EchoStar disclosed it would not make a $326 million interest payment on its senior spectrum secured notes, resulting in a further stock price decline of $2.44, or 12.1%, closing at $17.73 [4]. Group 3: Company Challenges - EchoStar has faced challenges in its efforts to build a nationwide 5G network for Boost Mobile, with the project described as slow-going despite significant investments in infrastructure [3]. - The uncertainty regarding EchoStar's spectrum rights has hindered its ability to make strategic decisions about its Boost business and overall business plan [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Travere Therapeutics, Inc. and its officers or directors [1] Group 1: Company Developments - On May 15, 2025, Travere announced that the FDA plans to hold an advisory committee meeting regarding its supplemental New Drug Application for FILSPARI, aimed at treating focal segmental glomerulosclerosis [3] - Following the FDA announcement, Travere's stock price dropped by $4.35 per share, a decline of 20.57%, closing at $16.80 per share on May 16, 2025 [3] Group 2: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4] - The firm has successfully recovered numerous multimillion-dollar damages awards for class members over its 85-year history [4]

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving NeuroPace, Inc. and its officers or directors [1]. Group 1: Company Performance - On May 27, 2025, NeuroPace announced the preliminary one-year results of the NAUTILUS study, which evaluated the safety and effectiveness of the RNS System for treating drug-resistant idiopathic generalized epilepsy (IGE) [3]. - The study did not achieve statistical significance for its primary effectiveness endpoint, which aimed to demonstrate a longer time to a second generalized tonic-clonic seizure in the active stimulation group compared to the sham stimulation group [3]. - Following the announcement, NeuroPace's stock price dropped by $5.02 per share, representing a decline of 28.39%, closing at $12.66 per share on the same day [3]. Group 2: Legal Investigation - Pomerantz LLP is reaching out to investors of NeuroPace to gather information related to the investigation of potential securities fraud [1]. - The firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Semler Scientific Inc. and its officers or directors [1] Group 1: Legal Investigation - Pomerantz LLP is representing investors of Semler Scientific Inc. in an investigation regarding possible securities fraud [1] - The investigation follows Semler's disclosure of a risk related to a potential complaint from the U.S. Department of Justice regarding the company's reimbursement claims for its QuantaFlo device [3] Group 2: Financial Impact - Following the news of the investigation and the DOJ's involvement, Semler's stock price dropped by $4.03, or 9.4%, closing at $38.89 per share on March 3, 2025 [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Savara Inc. and its officers or directors, following a significant stock price drop after negative FDA news [1][3]. Group 1: Investigation Details - Pomerantz LLP is representing investors of Savara Inc. and is looking into claims of securities fraud or other unlawful business practices [1]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the investigation [1]. Group 2: Stock Performance - On May 27, 2025, Savara announced it received a refusal to file letter from the FDA regarding its Biologics License Application for MOLBREEVI, leading to a stock price decline of $0.90 per share, or 31.69%, closing at $1.94 per share [3].

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Eos Energy Enterprises, Inc. (“Eos” or the “Company”) (NASDAQ: EOSE).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Eos and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 27, ...